WP
CLDX icon

Woodline Partners’s Celldex Therapeutics CLDX Stock Holding History

Woodline Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1M Buy
700,830
+200,703
+40% +$6.48M 0.08% 312
2026
Q1 		$15.9M Hold
500,127
– – 0.06% 389
2025
Q4 		$13.6M Buy
500,127
+300,836
+151% +$7.92M 0.05% 387
2025
Q3 		$5.16M Sell
199,291
-1,301,164
-87% -$30.2M 0.02% 563
2025
Q2 		$30.5M Buy
1,500,455
+312,026
+26% +$6.07M 0.16% 189
2025
Q1 		$21.6M Sell
1,188,429
-825,586
-41% -$18.4M 0.14% 216
2024
Q4 		$50.9M Sell
2,014,015
-327,106
-14% -$8.89M 0.34% 78
2024
Q3 		$79.6M Buy
2,341,121
+1,583,350
+209% +$60.3M 0.67% 24
2024
Q2 		$28M Buy
757,771
+6,711
+0.9% +$253K 0.27% 116
2024
Q1 		$31.5M Buy
751,060
+363,408
+94% +$14.9M 0.29% 105
2023
Q4 		$15.4M Buy
387,652
+280,156
+261% +$8.24M 0.17% 180
2023
Q3 		$2.96M Buy
107,496
+52,997
+97% +$1.66M 0.03% 365
2023
Q2 		$1.85M Sell
54,499
-972
-2% -$32.8K 0.02% 440
2023
Q1 		$2M Buy
+55,471
New +$2.39M 0.03% 425
2022
Q3 		– Sell
-64,454
Closed -$1.74M – 765
2022
Q2 		$1.74M Sell
64,454
-514,738
-89% -$14.9M 0.03% 452
2022
Q1 		$19.7M Buy
579,192
+319,297
+123% +$10.2M 0.32% 92
2021
Q4 		$10M Buy
+259,895
New +$11.3M 0.14% 194

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's CLDX Position: Q2 2026 in Review

Woodline Partners increased its Celldex Therapeutics (CLDX) stake by 40% in Q2 2026, buying an estimated $6.48M and bringing the position to 700,830 shares worth $26.1M. The position accounts for 0.08% of the portfolio, ranked #312.

Woodline Partners first reported a position in CLDX in Q4 2021 and has held it in 17 quarters since. The position peaked at $79.6M in Q3 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Woodline Partners held 700,830 shares of Celldex Therapeutics worth $26.1M as of Q2 2026.
  • Woodline Partners bought 200,703 Celldex Therapeutics shares in Q2 2026, an estimated $6.48M.
  • Celldex Therapeutics made up 0.08% of Woodline Partners's portfolio in Q2 2026, its #312 holding.
  • Woodline Partners first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Woodline Partners's Celldex Therapeutics position peaked at $79.6M in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.